Company Overview

Arsenal Medical, founded by George Whitesides and Robert Langer, is a platform technology company developing novel, therapeutic in-situ forming materials. In 2011, Arsenal Medical spun out Lyra Therapeutics to advance our clinical-stage drug delivery system that provides a steady dose of drug directly to diseased tissues.

June 5, 2017

U.S. FDA grants Arsenal Medical investigational device exemption approval to conduct clinical ResQFoam study

View Press Release


Arsenal Medical’s in-situ forming polymeric foam, ResQFoam, is designed to control severe, intra-cavity hemorrhage by creating conformal contact and applying pressure to an actively bleeding site. Treatment consists of an injection of two liquid polymers that react upon combining to create a foam that expands rapidly through actively flowing blood to compress the injury and control bleeding.

Learn More

Abdominal Aortic Aneurysm

Arsenal Medical is developing a system that injects an in-situ curing elastomeric polymer material that fills and seals the aneurysm sac around a stent graft. The material is designed to flow around the graft and cure into an elastic solid. Filling the sac seals off branch vessels that can cause aneurysm expansion, enhances graft seals to minimize endoleaks, and stabilizes graft position to prevent migration.

Learn More